Tranzactioneaza Sensei Biotherapeutics (US.SNSE) - 14.07 USD (%) Tranzactioneaza
Indici
Descriere companie
Sensei Biotherapeutics, Inc. (https://www.senseibio.com/) is a clinical-stage immunotherapy company. The Company is engaged in the discovery and development of therapies with focus on treatments for cancer. Its ImmunoPhage platform is a self-adjuvanted and differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response. The Company is engineering its ImmunoPhage product candidates to directly target antigen presenting cells (APCs) and modulate the tumor microenvironment (TME) through the targeted use of nanobodies which enhances therapeutic activity. SNS-301 is an ImmunoPhage product candidate that the Company is developing as a treatment for locally advanced unresectable or metastatic squamous cell carcinoma of the head and neck (SCCHN). It also develops ImmunoPhage candidate, SNS-401, for the treatment of Merkel cell carcinoma (MCC). The Company is also engaged in developing a monoclonal antibody (mAb) therapy.